Recent discovery and development of non-peptide vasopressin V2 receptor agonists

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 8, 2002, Pages 1249-1258

  Kondo, Kazumi ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Agonist; Arginine vasopressin (AVP); Bioavailability; Diabetes insipidus; Mimic; Modulator; Nocturia; Nocturnal enuresis; non peptide; Orally effective; Polyuria; Receptor; V2 receptor; Vasopressin

Indexed keywords

2 [1 (2 CHLORO 4 PYRROLIDIN 1 YLBENZOYL) 2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 5 YL] N ISOPROPYLACETAMIDE; 3 METHYL 1H PYRAZOLE BENZODIAZEPINE DERIVATIVE; 5 CHLOROBENZODIAZEPINE DERIVATIVE; 5 METHYL 1H 1,2,4 TRIAZOLE BENZODIAZEPINE DERIVATIVE; 5,6,7,8 TETRAHYDRO 4H THIENO[3,2 B]AZEPINE DERIVATIVE; 6,11 DIHYDRO 5H PYRIDO[2,3 B][1,5]BENZODIAZEPINE 1 OXIDE DERIVATIVE; 6,11 DIHYDRO 5H PYRIDO[2,3 B][1,5]BENZODIAZEPINE DERIVATIVE; [2 CHLORO 4 (3 METHYL PYRRAZOLE 1 YL)PHENYL] (5H,11H) PYRROLO[2,1 C][1,4]BENZODIAZEPINE 10 YLMETHANONE; AMIDE; ARGIPRESSIN; AZEPINE DERIVATIVE; BENZAZEPINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; DESMOPRESSIN; ESTER DERIVATIVE; ETHYNYL DERIVATIVE; HORMONE RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE; NON PEPTIDE VASOPRESSIN V2 RECEPTOR AGONIST; OPC 51803; PROPYLAMINE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDOBENZODIAZEPINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE 2 CARBOXAMIDE; PYRROLIDINE DERIVATIVE; THEINO[3,4 B][1,5]BENZOXAZEPINE DERIVATIVE; THIENOAZEPINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN V2 RECEPTOR;

BINDING AFFINITY; BLOOD DISEASE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES INSIPIDUS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NOCTURIA; NOCTURNAL ENURESIS; NONHUMAN; PREDICTION; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0036678747     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.8.1249     Document Type: Review

References (64)

1. Vascular smooth muscle and neurohypophyseal hormones
2. Characterization of human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function
3. Vasopressin receptor from cultured mesangial cells resemble V1a type
4. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture
5. Characterization of human platelet vasopressin receptors
6. 8-vasopressin binding to rat kidney and brain tissue
7. SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatto)
8. SK&F 105494: A potent antidiuretic hormone antagonist devoid of partial agonist activity in dogs
9. Vasopressin receptor antagonism in rhesus monkey and man: Stereochemical requirements
10. From vasopressin antagonist to agonist: A saga of surprise
11. 1 receptor antagonist
12. 1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihydro-2(1H)-quinolinone
13. 1a antagonists: 1-(1-multi-substituted benzoyl 4-piperidyl)-3,4-dihydro-2(1H)-quinolinones
14. 1 receptor of rat, rhesus and human tissues
15. 1 vasopressin receptors
16. 1a receptors
17. 1a antagonist, to rat and human liver membranes
18. Characterization of rodent liver and kidney AVP receptors: Pharmacologic evidence for species differences
19. 1-(1-[4-[(N-acetyl-4-piperidinyl) oxy]-2-methoxybenzoyl]piperidin-4-yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): A new, orally bioavailable, non-peptide oxytocin antagonist
20. Non-peptide oxytocin antagonists: Potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridiyl)ethyl ether terminus
21. Development of orally-active oxytocin antagonists: Studies on 1-(1-{4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl) piperidin-4-yloxy]-2-methoxybenzoyl}piperidin-4-yl)-1,4-dihydrobenz[d] [1,3]oxazin-2-one (L-372,662) and related pyridines
22. Non-peptide oxytocin antagonists: Analogs of L-371,257 with improved potency
23. Identification of potent and selective oxytocin antagonists. Part 1: Indole and benzofuran derivatives
24. 2 receptor antagonist
25. Potent aquaretic agent. A novel non-peptide selective vasopressin 2 antagonist (OPC-31260) in men
26. 2 receptor antagonists on progressive renal failure in rats
27. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
28. 2 antagonist in men
29. 2 receptor antagonists: A novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds
30. 2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats
31. 2 receptor antagonist
32. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats
33. 2 receptor antagonist
34. 2receptor antagonist
35. 2 receptor antagonist
36. 2 receptors: Synthesis and pharmacological properties of 2-phenyl-4′-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl] benzanilide derivatives
37. 2 receptors: Synthesis and pharmacological properties of 2-phenyl-4′-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide derivatives
38. 2 receptors: Synthesis and pharmacological properties of 4′-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl] benzanilide 4′-[5-(substituted methyl)-2,3Dihydro-1H-1-benzoazepine-1-carbonyl]benzanilide derivatives
39. 2 receptors: Synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo [4,5-d][1]benzoazepine-6-carbonyl) 4′-(5,6-dihydro-4H-thiazolo[5,4-d] [1]benzoazepine-6-carbonyl)benzanilide derivatives
40. 2 receptors: Synthesis and 4′-[(4,4-difluoro-5-methylidene- 2,3,4,5-tetrahydro-1H-1-benzoazepin-1-yl)carbonyl]-2-phenylbenzanilide derivatives
41. 2 receptors
42. The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepines
43. 2 receptor-selective antagonists, pyrrolo[2,1-a]quinoxaline and pyrrolo[2,1-c][1,4]benzodiazepine derivatives
44. 2 receptor antagonists
45. Small molecule ligands for oxytocin and vasopressin receptors
46. Discovery and development of non-peptide antagonists of peptide hormone receptors
47. 2 receptor antagonists
48. Non-peptide ligands for peptide and protein receptors
49. Vasopressin receptor modulators: From non-peptide antagonists to agonists
50. 1a vasopressin receptor
51. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor
52. Molecular cloning of the receptor for human antidiuretic hormone
53. 1b vasopressin receptor
54. Structure and expression of a human oxytocin receptor
55. Identification of agonist binding sites of vasopressin and oxytocin receptors
56. Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family
57. 1 vascular vasopressin receptor
58. 1a vasopressin receptor
59. 2 receptor agonists: Structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a template
60. 2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes
61. 2-receptor agonist, OPC-51803, administered orally to rats
62. 2 receptor agonist, produces potent antidiuretic effects in conscious rats, dogs and monkeys
63. 2-receptor agonist VNA-932
64. 2 receptor selective agonist